Pacira Biosciences Grants Molteni Exclusive Rights to Commercialize EXPAREL in EU, UK
MT newswire2026/10/05 12:4108:41 AM EDT, 10/05/2026 (MT Newswires) -- Pacira Biosciences (PCRX) said Monday it has granted Molteni Farmaceutici exclusive rights to distribute and commercialize EXPAREL in the European Union and the United Kingdom. Under the agreement, Pacira will receive an undisclosed upfront payment, a supply price and royalties on future sales of EXPAREL, a local analgesic for postsurgical pain management. Pacira will manufacture the product. Molteni will lead regulatory, market-access and commercialization activities across the licensed territories, Pacira said. The company plans to launch EXPAREL sequentially in Italy, Germany, Austria and Poland, while pursuing approval in Switzerland. The first commercial sale is expected in 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
